Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab

Brett A. Schroeder; Karan Kohli; Ryan B. O’Malley; Theresa S. Kim; Robin L. Jones; Robert H. Pierce; Seth M. Pollack

doi:10.1080/2162402X.2019.1710064

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab

Brett A. Schroeder^*, Karan Kohli, Ryan B. O’Malley, Theresa S. Kim, Robin L. Jones, Robert H. Pierce, Seth M. Pollack

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted.

Original language	English (US)
Article number	1710064
Journal	OncoImmunology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2019.1710064
State	Published - Jan 1 2020
Externally published	Yes

Keywords

GIST
Imatinib
Metastatic
Nivolumab
PD-1
PD-L1
Refractory
Sarcoma
Wild-Type

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.1080/2162402X.2019.1710064

Cite this

@article{1722a13f927a4220b046a0ed68a7ff10,

title = "Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab",

abstract = "Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted.",

keywords = "GIST, Imatinib, Metastatic, Nivolumab, PD-1, PD-L1, Refractory, Sarcoma, Wild-Type",

author = "Schroeder, {Brett A.} and Karan Kohli and O{\textquoteright}Malley, {Ryan B.} and Kim, {Theresa S.} and Jones, {Robin L.} and Pierce, {Robert H.} and Pollack, {Seth M.}",

note = "Publisher Copyright: {\textcopyright} 2020, {\textcopyright} 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2020",

month = jan,

day = "1",

doi = "10.1080/2162402X.2019.1710064",

language = "English (US)",

volume = "9",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab

AU - Schroeder, Brett A.

AU - Kohli, Karan

AU - O’Malley, Ryan B.

AU - Kim, Theresa S.

AU - Jones, Robin L.

AU - Pierce, Robert H.

AU - Pollack, Seth M.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted.

AB - Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted.

KW - GIST

KW - Imatinib

KW - Metastatic

KW - Nivolumab

KW - PD-1

KW - PD-L1

KW - Refractory

KW - Sarcoma

KW - Wild-Type

UR - http://www.scopus.com/inward/record.url?scp=85077848058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077848058&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2019.1710064

DO - 10.1080/2162402X.2019.1710064

M3 - Article

C2 - 32002307

AN - SCOPUS:85077848058

SN - 2162-4011

VL - 9

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 1710064

ER -